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Introduction 
CESM is a novel technique combining the benefits of iodinated contrast with standard mammographic views.  Dual energy acquisitions during one            
exposure yield two sets of images - a  Low Energy (LE)  set, equivalent to standard Full Field Digital Mammography (FFDM) [1], and a  recombined  set         
displaying contrast uptake.  Despite encouraging data from Europe and the US, there is no UK data to support its use as a tool in the diagnosis and staging of 
breast cancer. 
 
Method 
Since November 2013, we have routinely performed CESM within our symptomatic breast service, according to local departmental guidelines.                      
Women 35-70 years with a P4/5 [2] clinical abnormality are offered CESM  instead of  FFDM as an initial imaging test.   We also offer CESM to younger          
women whose ultrasound is suspicious, or who have biopsy-proven malignancy.  All patients undergoing CESM give written consent for the procedure,    
which includes subsequent use of their anonymised images for education and training purposes.   
This is a retrospective, multireader study comparing LE images alone, to the entire CESM examination (i.e. LE and recombined images). Consecutive CESM 
examinations were anonymised and stored as teaching files on the local PACS system by staff who were not involved in the subsequent image review.   
5 consultant radiologists (with 8-25 years of breast imaging experience) read the LE images in isolation, scoring any abnormalities using a 5 point scale [3].  At 
least 3 weeks later, the process was repeated, analysing both the LE and the recombined images. Brief, anonymised, clinical information was available to the 
readers for both reads. 
Pathology data were obtained for all cases.  Differences in performance were assessed using receiver operative characteristic (ROC) analysis.                    
Sensitivity, specificity and lesion size (vs. MRI or histopathology*) were analysed using 2­way independent t­test. 
*Where patients underwent neoadjuvant chemotherapy, size was compared with reported size at baseline MRI scan.  Where patients had surgery as their initial therapy, size was compared with reported              
histopathological (whole tumour) size. 
Results 
50 CESM examinations were analysed in this preliminary study.  All were female, with a mean age of 
49 years (range 25-69).  34 (68%) patients had biopsy proven malignancy, 16 (32%) patients were 
deemed benign following local clinical guidelines, including triple assessment as appropriate.  CESM 
showed increased sensitivity compared with LE alone (94% vs. 86%, p<0.025), increased specificity 
compared with LE alone (84% vs. 63%, p<0.025) and better size estimation (mean size difference 
23% vs. 31%, p<0.025). ROC analysis showed overall performance of CESM was significantly better 
than LE alone (Fig.1). 
 
Test Result 
Variable(s) 
Area Under 
The Curve 
95% Confidence Interval 
P Value 
Lower Bound Upper Bound 
Low Energy Alone 0.848 0.802 0.895 
P=0.0025 
CESM 0.933 0.899 0.966 
Conclusion 
This preliminary study demonstrates the additional clinical utility of CESM in symptomatic patients.  Its potential use in other clinical settings (e.g. screening of 
high-risk women), requires evaluation. 
Case Study 
58y F with a suspicious mass in the left central breast.  The palpable lesion is occult on the LE 
images (A).  Recombined images (B) demonstrate two ill-defined masses with a total extent of 
34mm in the left retro-areolar region. A 7mm focus of enhancement is also evident in the medial 
aspect on the left, away from the palpable tumour. Targeted ultrasound of the medial breast 
revealed a 5mm mass.  Core biopsies of the palpable tumour and the distal focus showed G2 
carcinoma with lobular features. The patient underwent mastectomy. Final histology confirmed 
two clearly separate carcinomas measuring 24 mm and 6 mm. 
Fig.1 - ROC 
analysis 
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